Chidozie Ugwumba has filed an amended Schedule 13G with the Securities and Exchange Commission, disclosing a 19.9% ownership stake in Clene Inc., a biopharmaceutical company. The filing, dated September 30, 2024, indicates that Ugwumba beneficially owns 2,249,661 shares of Clene's common stock, which includes shares issuable upon the exercise of various warrants. The disclosure follows Ugwumba's resignation from Clene's board of directors on February 15, 2023, and asserts that his holding is for investment purposes and not intended to change or influence control of the company. The reported ownership percentage is based on the total number of Clene's shares outstanding as of September 30, 2024, plus additional shares that could be acquired through warrant exercises, subject to a cap that prevents ownership exceeding 19.9% of voting securities.

Chidozie Ugwumba has filed an amended Schedule 13G with the Securities and Exchange Commission, disclosing a 19.9% ownership stake in Clene Inc., a biopharmaceutical company. The filing, dated September 30, 2024, indicates that Ugwumba beneficially owns 2,249,661 shares of Clene's common stock, which includes shares issuable upon the exercise of various warrants. The disclosure follows Ugwumba's resignation from Clene's board of directors on February 15, 2023, and asserts that his holding is for investment purposes and not intended to change or influence control of the company. The reported ownership percentage is based on the total number of Clene's shares outstanding as of September 30, 2024, plus additional shares that could be acquired through warrant exercises, subject to a cap that prevents ownership exceeding 19.9% of voting securities.